Clinical Trial13 Mar 2026, 06:41 pm
Dr. Reddy’s Labs Partner Immutep Discontinues Phase III Trial for Eftilagimod Alfa in Lung Cancer
AI Summary
Dr. Reddy’s Laboratories Ltd. announced that its partner, Immutep SAS, has decided to discontinue the Phase III TACTI-004 study evaluating Eftilagimod Alfa (efti) in firstline non-small cell lung cancer. The Independent Data Monitoring Committee (IDMC) recommended the discontinuation following a planned interim futility analysis. Immutep will halt enrolment, implement a wind-down of the study, and review the available data to determine next steps. Dr. Reddy’s SA, a subsidiary of Dr. Reddy’s Laboratories Limited, has made only the upfront payment to Immutep and continues to engage in discussions on the appropriate way forward.
Key Highlights
- Immutep discontinues Phase III TACTI-004 study for Eftilagimod Alfa in lung cancer
- IDMC recommendation followed review of safety and efficacy data
- Dr. Reddy’s SA made only upfront payment to Immutep
- Immutep to review available data and determine next steps
- Dr. Reddy’s SA and Immutep continue discussions on appropriate way forward